{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:35:37Z","timestamp":1759336537268,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.arteri.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T08:16:43Z","timestamp":1560586603000},"page":"263-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perfil de seguridad de los anticoagulantes directos. Uso preferente en fibrilaci\u00f3n auricular"],"prefix":"10.1016","volume":"31","author":[{"given":"Inmaculada","family":"Rold\u00e1n Rabad\u00e1n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Alonso de Leci\u00f1ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Barba Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"P\u00e1ramo Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2019.03.002_bib0175","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2019.03.002_bib0180","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1093\/eurheartj\/ehu374","article-title":"Prognosis and treatment of atrial fibrillation patients by European cardiologists: One year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2019.03.002_bib0185","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.recesp.2015.03.007","article-title":"Tratamiento antiarr\u00edtmico actual de la fibrilaci\u00f3n auricular no valvular en Espa\u00f1a. Datos del Registro FANTASIIA","volume":"69","author":"Rold\u00e1n","year":"2016","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.arteri.2019.03.002_bib0190","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2019.03.002_bib0195","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKETAF Investigators. Rivaroxaban versus warfarin in non valvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2019.03.002_bib0200","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2019.03.002_bib0205","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2019.03.002_bib0210","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2019.03.002_bib0215","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation Undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2019.03.002_bib0220","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2019.03.002_bib0225","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1161\/STROKEAHA.117.017549","article-title":"Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation. A systematic review and meta-analysis","volume":"48","author":"Ntaios","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2019.03.002_bib0230","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.recesp.2016.03.004","article-title":"En el camino de un mejor uso de los anticoagulantes en la fibrilaci\u00f3n auricular no valvular. Propuesta de modificaci\u00f3n del posicionamiento terap\u00e9utico UT\/V4\/23122013","volume":"69","author":"Rold\u00e1n","year":"2016","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.arteri.2019.03.002_bib0235","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00415-013-6939-6","article-title":"Intracerebral hemorrhage during anticoagulation with vitaminK antagonists: A consecutive observational study","volume":"260","author":"Horstmann","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.arteri.2019.03.002_bib0240","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CRD.0000000000000088","article-title":"Non-vitamin K antagonist oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation: A meta-analysis of randomized controlled trials","volume":"24","author":"Kumar","year":"2016","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.arteri.2019.03.002_bib0245","first-page":"1486","article-title":"New oral anticoagulants and the risk of intracranial hemorrhage: Traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation","volume":"70","author":"Chatterjee","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.arteri.2019.03.002_bib0250","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.thromres.2015.07.001","article-title":"Intracranial haemorrhage in patients treated with direct oral anticoagulants","volume":"136","author":"Beynon","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.arteri.2019.03.002_bib0255","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00701-016-3026-7","article-title":"Clinical and radiological course of intracerebral haemorrhage associated with the new non-vitaminK anticoagulants","volume":"159","author":"Von der Brelie","year":"2017","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.arteri.2019.03.002_bib0260","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1160\/TH13-04-0318","article-title":"Questionable reversal of anticoagulation in the therapeutic management of cerebral haemorrhage associated with vitaminK antagonists","volume":"110","author":"Alonso de Leci\u00f1ana","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.arteri.2019.03.002_bib0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jamaneurol.2015.3682","article-title":"Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants","volume":"73","author":"Purrucker","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.arteri.2019.03.002_bib0270","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1212\/WNL.0000000000004362","article-title":"Direct oral anticoagulant- vs vitaminK antagonist-related nontraumatic intracerebral hemorrhage","volume":"89","author":"Tsivgoulis","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.arteri.2019.03.002_bib0275","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2019.03.002_bib0280","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ana.25079","article-title":"Oral anticoagulation and functional outcome after intracerebral hemorrhage","volume":"82","author":"Biffi","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.arteri.2019.03.002_bib0285","doi-asserted-by":"crossref","first-page":"e004517","DOI":"10.1161\/JAHA.116.004517","article-title":"Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: Contemporary findings in real-life Danish patients","volume":"6","author":"Lamberts","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arteri.2019.03.002_bib0290","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ajgsup.2016.3","article-title":"Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants","volume":"3","author":"Desai","year":"2016","journal-title":"Am J Gastroenterol Suppl"},{"key":"10.1016\/j.arteri.2019.03.002_bib0295","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jgh.13830","article-title":"New predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants: A cohort study","volume":"33","author":"Shimomura","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.arteri.2019.03.002_bib0300","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/1756283X17702092","article-title":"Direct oral anticoagulants and digestive bleeding: Therapeutic management and preventive measures","volume":"10","author":"Deutsch","year":"2017","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.arteri.2019.03.002_bib0305","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.ejim.2017.02.020","article-title":"Gastrointestinal bleeding during direct oral anticoagulant therapy. Is there nothing so bad that is not good for something?","volume":"39","author":"Pasin","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.arteri.2019.03.002_bib0310","doi-asserted-by":"crossref","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.arteri.2019.03.002_bib0315","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2016.11.117","article-title":"Major bleeding with vitaminK antagonists or direct oral anticoagulants in real-life","volume":"227","author":"Becattini","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.arteri.2019.03.002_bib0320","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11239-015-1167-9","article-title":"Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents","volume":"39","author":"Siegal","year":"2015","journal-title":"J Thromb Thrombolysis."},{"key":"10.1016\/j.arteri.2019.03.002_bib0325","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.blre.2016.08.006","article-title":"Measurement and reversal of the direct oral anticogulants","volume":"31","author":"Samuelson","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.arteri.2019.03.002_bib0330","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1160\/TH16-05-0363","article-title":"Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper","volume":"116","author":"Ageno","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.arteri.2019.03.002_bib0335","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal \u2014 Full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.arteri.2019.03.002_bib0340","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct anticoagulants: Guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916819300440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916819300440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:31:44Z","timestamp":1759325504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916819300440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0214916819300440"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2019.03.002","relation":{},"ISSN":["0214-9168"],"issn-type":[{"type":"print","value":"0214-9168"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perfil de seguridad de los anticoagulantes directos. Uso preferente en fibrilaci\u00f3n auricular","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}